Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non-Small-Cell Lung Cancer With Liver Metastases.

Wong WB, Wu N, Yang E, Davies J, Chae YK.

J Oncol Pract. 2019 Oct;15(10):e878-e887. doi: 10.1200/JOP.19.00166. Epub 2019 Sep 11.

PMID:
31509482
2.

Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE).

Bennouna J, Falchero L, Schott R, Bonnetain F, Coudert M, Ben Hadj Yahia B, Chouaid C.

Oncology. 2018;94(1):55-64. doi: 10.1159/000480702. Epub 2017 Oct 25.

PMID:
29065416
3.

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group.

Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.

PMID:
30922878
4.

Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer.

Shankaran V, Mummy D, Koepl L, Bansal A, Mirick DK, Yu E, Morlock R, Ogale S, Ramsey SD.

Oncologist. 2014 Aug;19(8):892-9. doi: 10.1634/theoncologist.2013-0209. Epub 2014 Aug 1.

5.

A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.

Norden AD, Korytowsky B, You M, Kim Le T, Dastani H, Bobiak S, Singh P.

J Manag Care Spec Pharm. 2019 Apr;25(4):428-436. doi: 10.18553/jmcp.2019.25.4.428.

6.

Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.

Borghaei H, Yim YM, Guerin A, Pivneva I, Shi S, Gandhi M, Ionescu-Ittu R.

Lung Cancer. 2018 May;119:112-119. doi: 10.1016/j.lungcan.2018.02.011. Epub 2018 Feb 21.

PMID:
29656745
7.

Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.

Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S.

Lung Cancer. 2014 Dec;86(3):350-7. doi: 10.1016/j.lungcan.2014.09.017. Epub 2014 Sep 30.

PMID:
25439437
8.

Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.

Bagley SJ, Talento S, Mitra N, Meropol NJ, Cohen RB, Langer CJ, Vachani A.

J Natl Compr Canc Netw. 2019 May 1;17(5):469-477. doi: 10.6004/jnccn.2018.7102.

9.

Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.

Spence MM, Hui RL, Chang JT, Schottinger JE, Millares M, Rashid N.

J Manag Care Spec Pharm. 2017 Feb;23(2):195-205. doi: 10.18553/jmcp.2017.23.2.195.

10.

Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.

Bittoni MA, Arunachalam A, Li H, Camacho R, He J, Zhong Y, Lubiniecki GM, Carbone DP.

Clin Lung Cancer. 2018 Sep;19(5):e629-e645. doi: 10.1016/j.cllc.2018.04.017. Epub 2018 May 7.

11.

The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation.

Loveman E, Jones J, Clegg AJ, Picot J, Colquitt JL, Mendes D, Breen DJ, Moore E, George S, Poston G, Cunningham D, Ruers T, Primrose J.

Health Technol Assess. 2014 Jan;18(7):vii-viii, 1-283. doi: 10.3310/hta18070. Review.

12.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

13.

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.

Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Kaur H, Charnsangavej C, Loyer EM.

JAMA. 2009 Dec 2;302(21):2338-44. doi: 10.1001/jama.2009.1755.

14.
15.

Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.

Zhu J, Sharma DB, Gray SW, Chen AB, Weeks JC, Schrag D.

JAMA. 2012 Apr 18;307(15):1593-601. doi: 10.1001/jama.2012.454.

16.

Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.

Asseburg C, Frank M, Köhne CH, Hartmann JT, Griebsch I, Mohr A, Osowski U, Schulten J, Mittendorf T.

Clin Ther. 2011 Apr;33(4):482-97. doi: 10.1016/j.clinthera.2011.04.010.

PMID:
21635994
17.

Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience.

Ritzwoller DP, Carroll NM, Delate T, Hornbrook MC, Kushi L, Bowles EJ, Loggers ET, Menter A.

J Thorac Oncol. 2014 May;9(5):692-701. doi: 10.1097/JTO.0000000000000127.

18.

Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.

Johnston S, Wilson K, Varker H, Malangone-Monaco E, Juneau P, Riehle E, Satram-Hoang S, Sommer N, Ogale S.

Clin Colorectal Cancer. 2017 Dec;16(4):386-396.e1. doi: 10.1016/j.clcc.2017.03.014. Epub 2017 Mar 24.

20.

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.

Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.

J Manag Care Spec Pharm. 2018 Jun;24(6):525-533. doi: 10.18553/jmcp.2018.24.6.525.

Supplemental Content

Support Center